Your Health, We Care
Koselugo achieved good results in the treatment of neurofibromatosis type I (NF1) and inoperable plexiform neurofibromatosis in a clinical trial published in The New England Journal of Medicine (NEJM).
The results showed that Koselugo effectively inhibited tumor growth, prolonged progression free survival, and had additional benefits in pain reduction, quality of life improvement, and other aspects.
Koselugo is a small molecule inhibitor targeting MEK, which plays the role of a ···【more】
Release date：2024-08-21Recommended：123
Koselugo is a small molecule MEK inhibitor and a repressor of mitogen activation···【more】
Release date：2024-08-21Recommended：146
Koselugois a small molecule MEK inhibitor (mitogen activation inhibitor), and it···【more】
Release date：2024-08-21Recommended：103
